STAT1 Interaction with E3-14.7K in Monocytes Affects the Efficacy of Oncolytic Adenovirus |
| |
| Authors: | Emma Spurrell Rathi Gangeswaran Pengju Wang Fengyu Cao Dongling Gao Baisui Feng William Wold Ann Tollefson Nicholas R Lemoine Yaohe Wang |
| |
| Institution: | aCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom;bSino-British Research Centre for Molecular Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;cDepartment of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA |
| |
| Abstract: | Oncolytic viruses based on adenovirus type 5 (Ad5) have been developed as a new class of therapeutic agents for cancers that are resistant to conventional therapies. Clinical experience shows that these agents are safe, but virotherapy alone has not achieved long-term cure in cancer patients. The vast majority of oncolytic adenoviruses used in clinical trials to date have deletion of the E3B genes. It has been demonstrated that the antitumor potency of the E3B-deleted mutant (dl309) is inferior to adenovirus with E3B genes intact. Tumors treated with dl309 show markedly greater macrophage infiltration than E3B-intact adenovirus. However, the functional mechanisms for this were not previously known. Here, we demonstrate that deletion of E3B genes increases production of chemokines by monocytes after adenovirus infection and increases monocyte migration. The E3B 14,700-Da protein (E3B-14.7K) inhibits STAT1 function by preventing its phosphorylation and nuclear translocation. The STAT1 inhibitor, fludarabine, rescues the effect of E3B-14.7K deletion by downregulating target chemokine expression in human and murine monocytes and results in an enhanced antitumor efficacy with dl309 in vivo. These findings have important implications for clinical use of E3B-deleted oncolytic adenovirus and other E3B-deleted adenovirus vector-based therapy. |
| |
| Keywords: | |
|
|
